Kneat.com Inc (KSI-X)

We like KSI, and we even covered the name in one of our latest podcast episodes (link to our discussion on KSI can be found here). 

KSI is a $630M healthcare SaaS company that provides solutions for data and document management. Good sales growth is expected over the next few years, although it is not yet profitable. It generates positive free cash flows, has a strong balance sheet, strong gross margins, and we feel it is at the turning point of becoming profitable. Overall, we like the name and have it in our Growth model portfolio.
Unlock Premium - Try 5i Free

Rare to find a high-quality, small-cap tech company in Canada with good management. High growth. Grew ARR last quarter by 60%, very impressive. Valuation of 7x may seem high by Canadian standards, but not compared to US peers. Targeting regulated industries that need a validation solution. No dividend.

Has the majority of the big-pharma household names as customers. Delivered on what they said they would over the years. Still quite a bit to go. Selling to both new customers and current installed base, a very good sign. Likes the metrics, management, the market, customer base.

They bring validation software to biopharma, and they do it well. The chart is strong. He's been adding shares. Before, they were losing as they invested in R&D, but now they're becoming profitable. He expects margins to expand quickly in coming years. When they win a client, it takes time to roll out that client. Growth is safe.

Software company that is based in Ireland. 
Offers compliance and validation software in life sciences business.
Currently has 8/10 of top pharma & 18/20 top bio-pharma companies as customers. 
Growing customer base at a rapid rate.
Very positive on outlook of business.
Will continue to own shares.